La science des champignons

Résumé PubMed complet

Inonotus obliquus (Chaga mushroom) is a medicinal basidiomycete rich in structurally diverse terpenoids, yet the biosynthetic enzymes responsible for sesquiterpene formation remain poorly understood. Here, we identified six UbiA-type terpene synthases (IoUbiA1-6) from the I. obliquus genome and functionally characterized them through heterologous expression in Aspergillus oryzae. GC-MS and NMR analyses demonstrated that IoUbiA1-4 catalyze the biosynthesis of bisabolane-type sesquiterpenes, including (+)-Z-α-bisabolene (1), (-)-β-curcumene (2), and (6R,7E)-α-bisabolene (3). Sequence alignment and mutational analyses revealed two highly conserved catalytic motifs, NQXXXXXXXED and QDXXDXXXD, that are essential for enzymatic activity, as alanine substitution of key residues completely abolished product formation. These results experimentally establish the catalytic significance of the conserved motifs in fungal UbiA-type terpene synthases. In addition, metabolic engineering of the mevalonate pathway in the A. oryzae expression host significantly increased 1 production from 3.99 to 61.13 mg/kg. This study expands the functional diversity of fungal UbiA-type terpene synthases, uncovers the molecular basis for bisabolane-type sesquiterpene biosynthesis in I. obliquus, and provides a foundation for the biotechnological production of valuable sesquiterpenoids.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Chaga ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Zhang L, Duan Y, Zhang Y, Wang C, Li C, Liu C
Revue : ACS chemical biology
Publication : 2026-10-12 · PMID 42857955 · DOI 10.1021/acschembio.6c00661

Résumé PubMed complet

Myocardial ischemic injury is characterized by impaired energy metabolism and oxidative stress, which contribute to cardiac dysfunction and disease progression. Ganoderma lucidum polysaccharide (GLP), a major bioactive component of Ganoderma lucidum, exhibits various pharmacological activities; however, its protective effects against myocardial ischemic injury and underlying mechanisms remain unclear. This study investigated the effects of GLP against isoproterenol (ISO)-induced myocardial ischemic injury and its involvement in metabolic regulation and oxidative stress. A mouse myocardial ischemic injury model was established by subcutaneous injection of ISO (2 mg/kg/day) for 11days. Mice were randomly divided into normal control, model, GLP treatment groups with GLP administered orally at 50 and 100 mg/kg/day, and at 50 mg/kg/day by intraperitoneal injection. An ISO-induced injury model in vitro was established using AC16 cardiomyocytes, which were pretreated with GLP (0.25 ~ 1.00 µg/mL) followed by ISO exposure (40 µM, 24 h). GLP significantly alleviated ISO-induced myocardial injury, reduced cardiac hypertrophy, improved histopathological alterations, and decreased serum AST and LDH activities in mice. Similar protective effects were observed in AC16 cells. Moreover, GLP restored myocardial energy metabolic homeostasis, by improving ATP, phosphocreatine, creatine, and total adenine nucleotides levels, while reducing cAMP accumulation. GLP also alleviated oxidative stress by decreasing malondialdehyde level and enhancing total superoxide dismutase activity. Furthermore, GLP increased the expression of AMPK-α2, phosphorylated AMPK-α2, PGC-1α, and PPAR-α in myocardial tissue. These findings suggest that GLP protects against ISO-induced myocardial ischemic injury by improving myocardial energy metabolism and reducing oxidative stress, with AMPK/PGC-1α/PPAR-α-related metabolic regulation potentially contributing to its cardioprotective effects.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang XT, Hu MQ, Wu SY, Feng JY, Xu X, Gan ZY, Gao JP
Revue : Journal of natural medicines
Publication : 2026-10-05 · PMID 42830376 · DOI 10.1007/s11418-026-02093-8

Résumé PubMed complet

Cordyceps militaris mycelial polysaccharides (IPS) possess diverse metabolic and bioactive properties, yet existing studies on their gastrointestinal digestion and prebiotic potential remain scarce. This study aims to investigate the changes of IPS at different digestive stages and its interactions with the gut microbiota. During simulated salivary digestion, no significant changes were observed in IPS. During simulated gastric digestion, the reducing sugar content of IPS significantly increased, while in simulated intestinal digestion, this value decreased. After in vitro fermentation, the total carbohydrate, reducing sugar levels, and pH of digested IPS declined to different extents. Microbiome profiling demonstrated that IPS markedly elevated the relative abundance of Firmicutes, whereas it suppressed the levels of Proteobacteria, especially the pathogenic genus Shigella. Furthermore, total short-chain fatty acids (SCFAs) increased from 0.77 mmol/L to 3.58 mmol/L after 24 h fermentation. Collectively, these results verify that IPS holds great potential to improve intestinal homeostasis and alleviate gut-related disorders.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Wang NY, Bi XY, Yang ZG, Dou GL, Li SH, Lu SR, Huang Y, Wang ZX, et al.
Revue : Journal of food science
Publication : 2026-10-01 · PMID 42817792 · DOI 10.1111/1750-3841.71418

Résumé PubMed complet

Polysaccharides from Bombyx mori-hosted Cordyceps militaris are abundant but exhibit limited bioactivity, necessitating exploration of sulfated derivatives. In this study, crude polysaccharides (Bm-CMP) were extracted and further sulfated to obtain four derivatives (Bm-sCMP-1∼4). Physicochemical and structural analyses indicated that sulfation significantly modified the characteristics of Bm-CMP, notably reducing the molecular weight (Mw) and particle size while enhancing the negative surface charge and altering the monosaccharide profile. All sulfated derivatives exerted enhanced inhibitory effects against Escherichia coli and Bacillus subtilis, which were closely dependent on the degree of substitution (DS), sulfate content, and negative charge density. Notably, Bm-sCMP-2, with a moderate DS, displayed the optimal antibacterial efficacy. Collectively, this work demonstrates that sulfation is a feasible strategy to valorize polysaccharides from B. mori-hosted C. militaris, transforming them into promising candidates for novel antibacterial agents, although their in vivo efficacy and safety require further validation.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Yang J, Cheng J, Li G, Shi W, Liu Y, Luo T, Zheng L
Revue : Chemistry & biodiversity
Publication : 2026-10-01 · PMID 42817574 · DOI 10.1002/cbdv.71798

Résumé PubMed complet

Nitrogen metabolism is fundamental to fungal growth, development, and the biosynthesis of bioactive metabolites. The GATA transcription factor AreA plays a pivotal regulatory role in nitrogen metabolite repression. While the molecular mechanisms by which AreA responds to nitrogen sources have been relatively well elucidated in ascomycetes, they remain poorly understood in basidiomycetes. Here, using the macrofungus Ganoderma lucidum as a model, we elucidated a molecular mechanism by which an N-acetyltransferase (Nat) influences AreA nuclear entry under non-preferred nitrogen sources, thereby promoting nitrogen catabolic gene expression and the utilization of non-preferred nitrogen sources. Through a yeast two-hybrid library screen, we identified Nat as an AreA-interacting protein, and their physical interaction was subsequently validated by yeast two-hybrid and bimolecular fluorescence complementation (BiFC) assays. In vitro acetylation assays coupled with mass spectrometry analysis demonstrated that Nat specifically acetylates lysine residues 619 and 916 of AreA. In vivo experiments further showed that silencing of nat reduced the acetylation level of AreA. Nitrate conditions induced the expression of nat and increased NAT protein levels, compared with ammonium conditions. Silencing of nat did not affect areA transcription or total AreA protein abundance; however, it significantly reduced nuclear AreA accumulation with a concomitant increase in cytoplasmic retention. Compared with the wild-type strain, nuclear AreA accumulation in the nat-silenced strain was reduced by approximately 70% under nitrate conditions. Consequently, the expression and enzymatic activity of AreA-regulated nitrogen metabolic genes, including glutamine synthetase (gs) and nitrate reductase (nr), were markedly suppressed. This study illuminates a post-translational mechanism by which non-preferred nitrogen sources activate AreA in basidiomycetes. It further reveals a role for protein acetylation in the nitrogen metabolism of G. lucidum, thereby expanding our understanding of nitrogen metabolic networks in fungi.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Li H, Qiao J, Zhang S, Huang A, Wu K, Ren A, Liu R, Shi L, et al.
Revue : Microbiological research
Publication : 2026-09-29 · PMID 42826594 · DOI 10.1016/j.micres.2026.128745

Résumé PubMed complet

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that causes memory loss, cognitive decline, and ultimately dementia. Available pharmacotherapies mainly provide symptomatic relief and do not adequately address the underlying pathology. Ganoderma lucidum (Curtis) P. Karst (G. lucidum) is a widely used medicinal mushroom rich in bioactive compounds, including polysaccharides, triterpenoids, and proteins. These constituents may alleviate the neuroinflammation and oxidative stress involved in AD pathogenesis. This review critically integrates evidence for the therapeutic effects of G. lucidum on AD-associated neuroinflammation and oxidative stress. It has three aims: (1) to examine how G. lucidum may disrupt the bidirectional vicious cycle between neuroinflammation and oxidative stress; (2) to compare the pharmacological profiles of different preparations and purified constituents; and (3) to evaluate AD-specific barriers to translation and inform future clinical development. We searched PubMed, Web of Science, Google Scholar, and CNKI for studies on G. lucidum and AD through 2026 using combinations of the primary term "Ganoderma lucidum" with "Alzheimer's disease," "neuroinflammation," "oxidative stress," and related terms. Included were original research, mechanism-based studies, and clinical evidence on G. lucidum bioactives in AD or related models. Evidence was stratified by design robustness and presented as a narrative synthesis. The available evidence indicates that G. lucidum may act on several pathological processes associated with AD. Experimental studies report effects on abnormal amyloid-β (Aβ) aggregation, tau hyperphosphorylation, cholinergic dysfunction, neuroinflammation, oxidative stress, and neuronal apoptosis. These findings illustrate the multi-target pharmacology of traditional Chinese medicines and help explain the potential activity of G. lucidum against AD. G. lucidum has anti-inflammatory, antioxidant, and neuroprotective activities that may be relevant to AD management. This review summarizes its reported effects on AD-related neuroinflammation and oxidative stress and examines the underlying mechanisms. Clinical translation remains limited by poor blood-brain barrier (BBB) permeability, uncertain pharmacokinetics, and non-standardized dosing. Rigorous preclinical studies and controlled early-phase trials are therefore required. Addressing these barriers may inform the potential translation of G. lucidum as an adjunctive strategy in multimodal AD therapy. We also identify key evidence gaps and propose a component-specific framework for future research.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Gao J, Zhang W, Yang F, Peng G, Zhang T, Dong T, Wang J
Revue : Journal of ethnopharmacology
Publication : 2026-09-29 · PMID 42810460 · DOI 10.1016/j.jep.2026.122442

Résumé PubMed complet

Inonotus obliquus is a medicinal fungus growing on birch bark. A neutral polysaccharide (IOP-W, Mw = 8.222 kDa) was isolated from its crude polysaccharides via sequential DEAE DE-52 cellulose column and Sephadex G-200 gel filtration column chromatography. IOP-W, composed primarily of galactose, glucose, and mannose, was structurally characterized by UV-Vis, FT-IR, GC-MS, and NMR as a glucan containing →4)-α-D-Glcp-(1→, →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, →4,6)-α-D-Glcp-(1→, terminal α-D-Glcp, and β-D-Glcp reducing end. AFM confirmed its aggregated spherical morphology. IOP-W exerted antitumor activity against MIA PaCa-2 cells by modulating apoptosis and migration. Metabolomics revealed effects on amino acids, alkaloids, lipids, and nucleotides involving 20 pathways, while transcriptomic KEGG analysis showed regulation of MAPK, TNF, and p53 signaling. In vivo investigations employing small animal MRI technology have validated that tumor growth is significantly suppressed in animal models, accompanied by elevated spleen index and improved physiological parameters. Western blotting and immunohistochemistry revealed altered expression of Parp-1, p53, Bax/Bcl-2, p-ERK1/2, p-JNK1, NF-κB, vimentin, and MMP-9. These findings indicate that IOP-W inhibits pancreatic cancer via the p53/MAPK pathway, highlighting its potential as a fungal polysaccharide-based therapeutic candidate.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Chaga ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Liu X, Zhu G, Wang L, Feng L, Jin X, Zhao J, Yang H, Li G, et al.
Revue : International journal of biological macromolecules
Publication : 2026-09-25 · PMID 42790566 · DOI 10.1016/j.ijbiomac.2026.154618

Résumé PubMed complet

Hemorrhagic fever with renal syndrome (HFRS) is frequently complicated by acute kidney injury (AKI). Although most patients recover from AKI with supportive care, some progress to chronic kidney disease (CKD). The incidence and determinants of CKD progression in patients with HFRS-AKI remain uncertain. Here, 99 patients with HFRS-AKI treated at Jinling Hospital were analyzed retrospectively to determine the rate of CKD progression and identify associated risk factors. Patients were divided into complete recovery (CR) and incomplete recovery (ICR) groups according to CKD progression. Baseline clinical and laboratory data were collected and analyzed. Overall, 27.3% of patients with HFRS-AKI progressed to CKD despite receiving supportive care. Facial flushing was more frequent in the ICR group than in the CR group (40.7% vs. 18.1%, p = 0.033). Multivariate analysis revealed that treatment with Cordyceps sinensis preparations during the AKI phase was an independent protective factor against incomplete kidney recovery (OR: 0.323, 95% CI: 0.114-0.916, p = 0.034). Inverse probability weighting analysis further demonstrated that the use of Cordyceps sinensis preparations was inversely associated with incomplete kidney recovery (β: -1.184, 95% CI: -2.224 - -0.144, p = 0.026). Survival analysis confirmed that Cordyceps sinensis preparation therapy was associated with improved kidney outcomes (log-rank test, p = 0.004). This study provides the first clinical evidence that adjunctive therapy with Cordyceps sinensis preparations during HFRS-AKI is associated with improved kidney outcomes, suggesting that Cordyceps sinensis preparations represents a promising therapeutic approach for viral-induced AKI.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Min M, Yu Y, Xing C, Zhang J
Revue : Renal failure
Publication : 2026-09-23 · PMID 42779256 · DOI 10.1080/0886022X.2026.2728349

Résumé PubMed complet

Ganoderma lucidum polysaccharides (GLPs), the core bioactive macromolecules of Ganoderma lucidum, have garnered massive research attention for their robust immunomodulatory effects. Cumulative data verify that GLP β-glucans specifically bind pattern recognition receptor Dectin-1, alongside auxiliary co-receptors for synergistic regulation. Dectin-1 engagement triggers the Syk-CARD9 cascade, promoting NF-κB nuclear translocation to upregulate immune genes and directly regulate macrophage polarization and dendritic cell maturation via Dectin-1, which in turn indirectly activates NK cells and T cells through cytokine release (IL-12, IL-18) and antigen presentation by matured dendritic cells. This review details GLP structural characteristics and corresponding structure-immunomodulation relationships, highlighting the pivotal Dectin-1/NF-κB signaling axis. It summarizes state-of-the-art GLP research in anti-tumor, anti-inflammatory therapy and immune homeostasis, clarifies molecular mechanisms, sorts preclinical outcomes, and addresses obstacles limiting clinical translation. GLPs are classified by raw sources, extraction protocols, molecular weight, monosaccharide components, glycosidic linkages and spatial conformations; each structural trait is paired with dedicated characterization and cell/animal verification assays to eliminate superficial structure-activity generalizations. This work lays theoretical groundwork for fungal polysaccharide immunomodulator preclinical development, yet human clinical trials remain indispensable.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Zheng J, Zuo Y, Wang Y, Sun Y, Chen Y, Huang Q, Yu M, Liu C
Revue : International journal of biological macromolecules
Publication : 2026-09-23 · PMID 42777993 · DOI 10.1016/j.ijbiomac.2026.154584

Résumé PubMed complet

The young sprouts pruned to ensure optimal growth of Ganoderma lucidum, called Ganoderma lucidum sprouts (GLS), are often discarded as waste despite being rich in polysaccharides (GLSP). Therefore, an ultrasonic-assisted extraction (UAE) method for GLSP was developed and optimized via entropy weight method-response surface methodology (EWM-RSM) considering yield, activity, and energy consumption with energy consumption treated as a negative indicator. Energy consumption and related greenness metrics were subsequently incorporated into the AGREEprep assessment, which evaluates sample preparation greenness across ten principles. The physicochemical properties, including thermal stability and functional groups, and in vitro activities were characterized. The results showed that the optimal conditions of UAE were as follows: power 280 W, liquid-to-material ratio 38:1 mL/g, ultrasonic time 27.5 min, and temperature 47°C. At this time, the extraction rate was 2.22% and the energy consumption was 0.292 Wh/sample. The AGREEprep evaluation confirmed that this extraction process is environmentally friendly and highly green. UAE had higher purity and better thermal stability compared with microwave-extraction and thermal reflux extraction, along with a yield increase of 24.02% and 47.02%. Infrared spectroscopy analysis further showed that UAE did not change the basic chemical skeleton of the polysaccharide, but there was a significant difference in the pyranose ring peak area. In addition, UAE performed better in terms of ABTS+ radical scavenging activity, hydroxyl radicals, total reducing power and nitrite scavenging activity. This UAE process provides a theoretical foundation and fresh perspectives on the effective extraction of GLSP and the high-value application of GLS.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Wang Y, Lai Y, Shi K, Chen Q, Li S, Wan P, Zhou H
Revue : Ultrasonics sonochemistry
Publication : 2026-09-23 · PMID 42777379 · DOI 10.1016/j.ultsonch.2026.108077

Résumé PubMed complet

The medicinal mushroom Hericium erinaceus is a rich source of diverse bioactive secondary metabolites. Erinacerins are a significant class of structurally diverse secondary metabolites, comprising both nitrogen-containing alkaloids bearing an isoindolinone or pyridinone core and non-nitrogenous congeners. This review provides a comprehensive overview of 28 known erinacerins reported from H. erinaceus, detailing their isolation, structural elucidation, and diverse bioactivities. A key focus is directed toward their characterization by NMR spectroscopy, offering a systematic guide for the identification of this class of molecules. The discussion encompasses the reported inhibitory effects of erinacerins against enzymes such as acetylcholinesterase and α-glucosidase, as well as their anti-inflammatory and cytotoxic activities against various cancer cell lines, underscoring their pharmacological potential. This work highlights the significance of erinacerins as a valuable scaffold of bioactive metabolites for therapeutic applications.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Lion’s Mane ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Othman A, Amen Y, Shimizu K
Revue : Journal of natural medicines
Publication : 2026-09-21 · PMID 42766259 · DOI 10.1007/s11418-026-02080-z

Résumé PubMed complet

Cordyceps militaris is an edible medicinal fungus with potential metabolic benefits, but its effects on type 2 diabetes mellitus accompanied by hyperlipidaemia (T2DM-HLP) remain incompletely understood. This study evaluated the effects of orally administered C. militaris ethanol extract (EAE; 2.0 g kg-1) and cordycepin (50 or 100 mg kg-1) in a T2DM-HLP mouse model over 6 weeks. Metabolic indices, serum transaminases, colon and liver histology, gut bacterial and fungal communities, serum metabolites, and FXR/TGR5-related molecular markers were assessed. Compared with the model group, EAE and 50 mg kg-1 cordycepin reduced serum lipid and transaminase levels to varying degrees and were associated with downward shifts in fasting blood glucose and oral glucose tolerance test curves. Histological alterations in the colon and liver were also less apparent in these two groups. Faecal 16S rDNA and ITS sequencing showed changes in the bacterial and fungal community structure, while untargeted serum metabolomics identified distinct metabolic profiles involving bile acids, fatty acids, amino acids, nucleotides, and redox-related metabolites. Enrichment analyses implicated bile secretion, primary bile acid biosynthesis, cholesterol metabolism, cAMP signalling, and amino acid metabolism. These changes were accompanied by increased colonic TGR5 and hepatic FXR immunoreactivity, increased hepatic Fxr, Nr0b2, and Ppara expression, and reduced Cyp7a1 expression. Responses to 100 mg kg-1 cordycepin were less consistent, indicating no simple dose-dependent relationship under the present conditions. Overall, EAE and cordycepin were associated with improved metabolic status and coordinated changes in the gut microbial composition, serum metabolism, and bile acid-related molecular readouts.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Shi H, Meng Y, Zhang G, Ling J
Revue : Food & function
Publication : 2026-09-21 · PMID 42695401 · DOI 10.1039/d6fo02540d

Résumé PubMed complet

Gemcitabine (GEM), a first-line chemotherapeutic agent, may fail to prevent recurrence in some settings. Traditional Chinese medicine emphasizes Yin-Yang balance and "fuzheng" approaches and may offer complementary strategies. Ganoderma lucidum polysaccharides (GLP) exhibit immune-enhancing activity, but evidence for direct anti-tumor efficacy, either alone or in combination with low-dose GEM, remains limited. Using a murine 4T1 breast cancer model, we integrated flow cytometry, 16S rRNA gene sequencing, and gas chromatography-mass spectrometry to evaluate the anti-tumor activity of GLP combined with low-dose GEM. GLP alone enhanced immune parameters but did not significantly suppress tumor growth, whereas low-dose GEM reduced tumor volume and activated anti-tumor immunity. Notably, the GLP plus GEM combination produced greater tumor inhibition than either treatment alone and was associated with increased IFN-γ and TNF-α levels, enhanced CD8+ T-cell infiltration, and enrichment of Ligilactobacillus, Duncaniella, and Faecalibaculum in the gut microbiota, and elevated serum levels of short-chain fatty acids and tryptophan. Notably, the antitumor effect in the combination group was accompanied by reduced tumoral IDO expression and elevated serum tryptophan, which were statistically correlated; however, as kynurenine levels were not quantified in this study, we cannot attribute this correlation to altered IDO enzymatic activity or establish a direct functional link along the IDO-tryptophan metabolic pathway. Thus, the combination of GLP and low-dose GEM exerts a synergistic anti-tumor effect.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang W, Chen G, Li S, Zhao P, Cheng C, Lu Z, Song Z
Revue : Molecular carcinogenesis
Publication : 2026-09-19 · PMID 42762514 · DOI 10.1002/mc.70178

Résumé PubMed complet

Cordycepin is an important nucleoside analogue and the principal active compound found in Cordyceps militaris. It exhibits anticancer, antiviral, immunomodulatory, and various other biological activities. However, the low cordycepin yields and high manufacturing costs limit its large-scale application. To develop a low-cost nutrient regulator to improve cordycepin production, we investigated the effect of corn steep liquor protein hydrolysate (CSLPH) on cordycepin biosynthesis during submerged fermentation of C. militaris, and the response mechanism of C. militaris to CSLPH utilization was revealed by comparative analysis of cell growth, cordycepin production, and transcriptomes. The results showed that a low CSLPH level in the medium stimulated the biosynthesis of cordycepin, and the addition of 1.0-3.5 g/L CSLPH in the medium increased the cordycepin production by 192.46% to 405.32%, which achieved the maximum cordycepin yield at a concentration of 1.5 g/L, and significantly promoted the growth of C. militaris after 14 days of fermentation. Transcriptomic analysis revealed that a set of significantly up-regulated genes in the pathway of cordycepin biosynthesis were enriched under CSL and CSLPH treatments, and some key up-regulated genes in the metabolic pathway of cordycepin biosynthesis were validated by quantitative real-time PCR. Moreover, transcriptomic analysis confirmed that the energy metabolism, amino acid metabolism, and the nucleotide pathway of Cordyceps militaris were improved by CSLPH, which facilitates cordycepin biosynthesis. Additionally, a cooperative mechanism by which CSLPH regulates cordycepin biosynthesis was elucidated for the first time in the current study. These results suggest that enzymatically hydrolyzed corn steep liquor is a more suitable alternative nitrogen source than corn steep liquor for efficient cordycepin production at low cost.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Chang Y, Liu X, Jiao Y, Zhao L
Revue : Bioprocess and biosystems engineering
Publication : 2026-09-18 · PMID 42754687 · DOI 10.1007/s00449-026-03410-x

Résumé PubMed complet

Cordyceps militaris is an edible entomopathogenic fungus with substantial nutritional and medicinal value. However, the molecular mechanisms underlying the vegetative mycelia-to-primordia (PR) transition and bioactive metabolite synthesis are still poorly defined. Deletion of the acyl-CoA dehydrogenase gene (ACAD) caused malformed, stunted PR-like structures together with excessive aerial mycelial growth, severely disrupting PR initiation and fruiting-body elongation in C. militaris. Transcriptomic, untargeted metabolomic and multi-omics analyses were performed on wild-type (WT) and ACAD-knockout strains at the mycelial and PR stages to explore gene expression reprogramming and bioactive nucleoside accumulation during the developmental transition and under ACAD deficiency. In total, 2014, 448, and 838 differentially expressed genes (DEGs) were identified in WT PR vs. WT mycelia, ΔACAD mycelia vs. WT mycelia, and ΔACAD PR vs. WT PR, demonstrating extensive transcriptional reprogramming during the development switch and upon ACAD deletion. KEGG enrichment and WGCNA analyses showed that ACAD deficiency significantly suppresses multiple reproductive-development pathways, including cell cycle progression, purine biosynthesis, the TCA cycle, MAPK signaling, redox homeostasis, fatty acid and amino acid metabolism. Consistently, ACAD deletion markedly increased intracellular ROS level and substantially reduced cellular ATP levels in mycelia. Several crucial genes modulated by ACAD were identified, including GTP cyclohydrolase I, histone lysine N-methyltransferase ASHR1, adenine phosphoribosyl transferase 1, glutathione-S-transferase F3 and CoA-ligase CCL8. Multi-omics integration demonstrated tightly coordinated transcriptional and metabolic regulation dependent on ACAD function. ACAD deficiency significantly disturbed amino acid, lipid, and nucleotide metabolism and reduced the abundance of amino acid derivatives, lipid compounds and purine nucleoside precursors in mycelia. Particularly, adenosine analogs serve as key precursors of the core bioactive nucleoside cordycepin. Key DEGs, including peroxisomal (S)-2-hydroxyacid oxidase, isocitrate lyase 2 and L-ascorbate peroxidase 5, were linked to these metabolic shifts. Our findings demonstrate that ACAD serves as an essential regulator that interconnects carbon metabolism, redox homeostasis, lipid, amino acid and purine metabolism to promote PR formation and secondary metabolite synthesis in C. militaris.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Zhou X, Xue L, Luo Y, Tong X, Guo J
Revue : Journal of fungi (Basel, Switzerland)
Publication : 2026-09-17 · PMID 42783991 · DOI 10.3390/jof12090696

Résumé PubMed complet

Obesity is a major global public health challenge. A high-fat diet (HFD) is a key contributing factor, closely associated with gut microbiota dysbiosis. Although immunomodulatory effects of Ganoderma lucidum spore oil (GLSO) have been reported, its role in lipid metabolism disorders and its interaction with gut microbiota remain incompletely understood. In this study, an HFD-induced obese mouse model was established and treated with GLSO (800 mg kg-1 day-1) for 82 days. Integrated analyses - including 16S rRNA sequencing, metabolomics, fecal fermentation of GLSO (FGLSO), and HepG2 cell experiments - were performed to evaluate metabolic effects and potential microbiota-related mechanisms. Ganoderma lucidum spore oil significantly reduced body weight gain, fasting blood glucose, serum lipid levels - including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) - and inflammatory markers, specifically tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). It also improved gut microbiota composition by increasing microbial diversity and enriching beneficial taxa such as Bacillus and unclassified_Muribaculaceae. These changes were accompanied by increased levels of short-chain fatty acids (SCFAs), particularly acetate and propionate, as well as alterations in bile acid metabolism. Further analysis suggested that metabolites may be associated with the regulation of hepatic lipid metabolism, potentially involving the peroxisome proliferator-activated receptor alpha (PPARα) signaling pathway. Fecal fermentation of GLSO exhibited stronger lipid-lowering effects than native GLSO in vitro, indicating that gut microbiota-mediated biotransformation may enhance the bioactivity of GLSO. Collectively, these findings suggest that GLSO alleviates HFD-induced metabolic disorders and highlight a potential role of gut microbiota in modulating its metabolic effects and enhancing its bioactivity. © 2026 Society of Chemical Industry.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang J, Yang Y, Zhou X, Yang W, Yuan Z, Liu J, Su A, Xie M, et al.
Revue : Journal of the science of food and agriculture
Publication : 2026-09-16 · PMID 42750144 · DOI 10.1002/jsfa.71035